Immuno-modulatory progenitor (IMP) cell

A method of producing a population of IMP cells, comprising

• (a) physically separating mononuclear cells (MCs) from bone marrow and culturing the MCs for 15 to 25 days in a medium consisting essentially of alpha Minimum Essential Medium (MEM), L-alanyl-L-glutamine dipeptide, platelet lysate, and heparin, at 0% oxygen (O2) supplied by an incubator and under conditions which allow the MCs to adhere to induce the MCs to differentiate into IMP cells and
• (b) harvesting and culturing the IMP cells in (a) to thereby produce the population, wherein harvesting comprises an antibody-based technique to select for a population in which
• (i) at least 90% of the cells in the population express detectable levels of MIC A/B,
• (ii) at least 60% of the cells in the population express detectable levels of CD304 (Neuropilin 1),
• (iii) at least 45% of the cells in the population express detectable levels of CD178 (FAS ligand),
• (iv) at least 10% of the cells in the population express detectable levels of CD289 (Toll-like receptor 9),
• (v) at least 15% of the population express detectable levels of CD363 (Sphingosine-1-phosphate receptor 1),
• (vi) at least 20% of the cells in the population express detectable levels of CD99,
• (vii) at least 80% of the cells in the population express detectable levels of CD181 (C-X-C chemokine receptor type 1;
• CXCR1),
• (viii) at least 30% of the cells in the population express detectable levels of epidermal growth factor receptor (EGF-R),
• (ix) at least 60% of the cells in the population express detectable levels of CXCR2
• (x) at least 5% of the cells in the population express detectable levels of CD126,
• (xi) at least 90% of the cells in the population express detectable levels of HLA-ABC,
• (xii) at least 90% of the cells in the population express detectable levels of CD340,
• (xiii) the cells express detectable levels of CD83,
• (xiv) the cells express detectable levels of CD86, and
• (xv) 1% or fewer of the cells express detectable levels of CD70 and wherein the platelet lysate is produced by subjecting a population of human platelets to four freeze-thaw cycles, wherein the freeze portion of each cycle is carried out in liquid nitrogen.